# Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The SIRONA Trial

> **NCT02587572** · PHASE2 · WITHDRAWN · sponsor: **Longeveron Inc.**

## Conditions studied

- Metabolic Disease
- Endothelial Dysfunction

## Interventions

- **BIOLOGICAL:** Peripheral Intravenous (IV) infusion of LMSCs

## Key facts

- **NCT ID:** NCT02587572
- **Lead sponsor:** Longeveron Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-12-01
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor has made decision not to conduct this clinical trial.
- **Last updated:** 2023-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02587572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02587572, "Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The SIRONA Trial". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02587572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*